Evidence map›Paper›PMID 41356015›Full record

ArticleFrontiers in endocrinology2025

Antidiabetic and lipid-lowering therapy modify the association between triglyceride-glucose index and acute kidney injury in critically ill patients with coronary artery disease.

Yuehang Yang, Linfeng He, Xueying Jiao, Hanshen Luo, Xiang Qiu, Chuli Shi, Li Ding, Jiawei Shi

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuehang Yang *Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Linfeng He *Department of Endocrinology and Metabolism, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
Xueying JiaoDepartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Hanshen LuoDepartment of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Xiang QiuDepartment of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Chuli ShiDepartment of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Li DingDepartment of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Jiawei ShiDepartment of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute kidney injury (AKI) is a common and serious complication in critically ill coronary artery disease (CAD) patients. The triglyceride-glucose (TyG) index, a surrogate marker of insulin resistance, has been linked to adverse cardiovascular and renal outcomes. However, whether antidiabetic drugs or lipid-lowering drugs modify its association with AKI in this population remains unclear. Methods: This study retrospectively analyzed 2,517 critically ill CAD patients from the MIMIC-IV database. Patients were stratified according to the use of antidiabetic and lipid-lowering drugs. The primary endpoint was the occurrence of AKI during hospitalization. Multivariable logistic regression and restricted cubic spline (RCS) models were applied to examine the association between the TyG index and AKI risk. Subgroup analyses, sensitivity analyses, and independent external validation were performed to assess the robustness of the findings. Results: The median age of patients was 69 years, and 68.06% were male. In the fully adjusted logistic regression model, a higher TyG index was significantly associated with an increased risk of AKI among patients without the use of antidiabetic drugs (OR 2.021, 95% CI 1.674-2.454) or lipid-lowering drugs (OR 1.912, 95% CI 1.648-2.228). With the use of antidiabetic drugs, this association remained significant but was attenuated (OR 1.480, 95% CI 1.190-1.853), with a significant interaction observed between the use of antidiabetic drugs and the TyG index in relation to AKI risk (P for interaction = 0.040). With the use of lipid-lowering drugs, the association between the TyG index and AKI risk was weakened (OR 1.445, 95% CI 0.934-2.307), but no significant interaction was found (P for interaction = 0.332). RCS analyses demonstrated a linear relationship between higher TyG index values and increased AKI risk. Similar results were confirmed in external validation. Conclusions: In critically ill CAD patients, a higher TyG index was independently associated with an increased risk of AKI, whereas this association was attenuated in those with the use of antidiabetic or lipid-lowering drugs. These findings highlight the importance of incorporating metabolic risk assessment into the management of critically ill patients and underscore the potential of pharmacological interventions to improve renal outcomes.

Indexed as

Acute Kidney InjuryBlood GlucoseCoronary Artery DiseaseHypoglycemic AgentsHypolipidemic AgentsTriglyceridesAgedBiomarkersCritical IllnessFemaleHumansMaleMiddle AgedRetrospective StudiesRisk FactorsBiomarkersBlood GlucoseHypoglycemic AgentsHypolipidemic AgentsTriglyceridesacute kidney injuryantidiabetic drugscoronary heart diseaselipid-lowering drugstriglyceride-glucose index

Identifiers

PMID41356015
PMCPMC12678119

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.